Andrew Oxtoby - 28 Feb 2023 Form 4 Insider Report for CHINOOK THERAPEUTICS, INC.

Role
Chief Commercial Officer
Signature
/s/ Kirk Schumacher, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
28 Feb 2023
Net transactions value
$0
Form type
4
Filing time
02 Mar 2023, 16:00:38 UTC
Previous filing
16 Feb 2023
Next filing
11 Aug 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KDNY Stock Option (right to buy) Award $0 +160,000 $0.000000 160,000 28 Feb 2023 Common Stock 160,000 $21.82 Direct F1
transaction KDNY Restricted Stock (RSU)(Common Stock) Award $0 +40,000 $0.000000 40,000 28 Feb 2023 Common Stock 40,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 25% of the total shares on February 28, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
F3 The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 28, 2024, until fully vested subject to the Reporting Person's provision of service to the Issuer on each vesting date.